SP Group (SPG) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
25 Aug, 2026Executive summary
Achieved record revenue and earnings in both Q2 and H1 2026, with H1 revenue up 32.9% to DKK 1,950 million and EBITDA up 36.2% to DKK 397 million, driven by strong organic growth and successful integration of acquisitions.
Expanded global footprint with the acquisition of OGM Moulding Ltd. in the UK and increased production capacity in Poland.
All product groups, including Cleantech, Foodtech, Healthcare, and others, saw sales growth.
Integration of Idé-Pro and OGM Moulding Ltd. progressing, expanding market presence and customer base.
Activity remains high despite geopolitical uncertainty and supply chain challenges.
Financial highlights
H1 2026 revenue rose 32.9% year-over-year to DKK 1,950 million, with organic growth of 19.7%.
EBITDA margin reached 20.3% and EBT margin 12.7% in H1 2026.
Q2 2026 revenue up 44.6% year-over-year; EBITDA up 59.9%; EBT up 91.9%.
Diluted EPS increased 55.1% to DKK 16.49 in H1 2026.
Operating cash flow for H1 2026 was DKK 291 million, up from DKK 229 million in H1 2025.
Outlook and guidance
2026 revenue growth guidance raised to 24-30% (previously 15-23%/22-28%), with expected revenue of DKK 3.6-3.8 billion.
Acquisitions expected to contribute 16-17% of growth; EBITDA margin guidance maintained at 19-21%, EBT margin at 11-13%.
High activity levels expected to continue, with ongoing supply chain and price challenges due to geopolitical factors.
Latest events from SP Group
- Record H1 2026 revenue and earnings growth led to an upgraded full-year outlook.SPG
Q2 2026 - Record Q1 2026 growth, robust outlook, and active capital returns amid global uncertainty.SPG
Q1 2026 - Record Q1 2026 revenue and profit growth, outlook and guidance remain robust.SPG
Q1 2026 - Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 2025 - Record Q4 and Idé-Pro acquisition set stage for strong 2026 growth amid ongoing uncertainties.SPG
Q4 2025 - H1 2025 saw lower revenue and earnings, but margin guidance and growth projects remain on track.SPG
Q2 2025 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 2024 - Q1 2025 delivered 8.8% revenue growth and margin expansion, with outlook unchanged.SPG
Q1 2025 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 2024